Target: Trk family | Disease State: Cancer

Introduction / Brief Description

LOXO-195 is an investigational, next-generation, selective tropomyosin receptor kinases (TRK) inhibitor designed to address potential mechanisms of acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity. Trk is a family of signaling proteins that are thought to play an important role in cellular communication and tumor growth. LOXO-195 is currently being evaluated in a Phase 1/2 trial.

In July 2013, Array initiated a multi-year license and collaboration agreement with Loxo Oncology for certain Array-invented compounds, including larotrectinib / LOXO-101, a Trk inhibitor; LOXO-292, a Ret inhibitor; and LOXO-195. In February 2019, Eli Lilly acquired Loxo Oncology. Bayer AG has exclusive rights to LOXO-195. The licensing agreement between Array and Loxo remains in effect.

Clinical Trials

To learn more about LOXO-195 clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.